Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Cancer Immunol Res. 2014 Feb 11;2(5):410–422. doi: 10.1158/2326-6066.CIR-13-0171

Table 1.

Tim-3 expression (%) and (MFI) according to demographic and clinical parameters with well-known prognostic value

Demographic and clinical parameters Number of patients (N=83(%)) Tim-3+ cells (%) Mean(SD) P value Tim-3+ cells (MFI) Mean(SD) P value
Age Groupsa <= 45y 22 (27) 71.77(10.78) 0.4122 31.30(5.953) 0.9363
46-70y 30 (36) 69.51(13.52) 30.94(6.650)
>=71y 31 (37) 66.34(18.15) 30.62(7.319)
Genderb Female 27 (33) 69.19(12.67) 0.7544 30.09(6.630) 0.4382
Male 56 (67) 69.28(15.85) 31.31(6.701)
Stagea I 47 (56) 66.01(15.78) 0.2116 29.07(5.303) 0.0114
II 18 (22) 69.93(17.45) 32.39(7.895)
III/IV 18 (22) 73.28(9.973) 34.30(8.479)
Thicknessb <=1mm 47 (57) 66.03(15.47) 0.041 29.18(5.642) 0.0059
>1mm 36 (43) 72.70(13.20) 33.18(7.166)
Mitotic Indexb <1/mm2 35 (42) 65.01(15.83) 0.0056 29.28(5.771) 0.0278
>=1/mm2 42 (51) 73.54(10.21) 32.46(6.540)
Unclassified 6 (7)
Ulcerationb Absent 58 (70) 67.51(15.34) 0.0351 30.19(6.263) 0.0466
Present 19 (23) 75.58(9.979) 33.61(6.811)
Unclassified 6 (7)
LN statusb Negative 70 (84) 68.24(15.58) 0.3280 30.85(6.875) 0.8242
Positive 13 (16) 72.64(9.389) 31.30(5.647)
Metastasisb Absent 74 (89) 68.10(15.22) 0.1476 30.26(6.105) 0.0092
Present 9 (11) 75.70(8.996) 36.31(8.840)
a

One-way analysis of variance (ANOVA);

b

Unpaired T test